Nagasato, Daisuke Saneikai Tsukazaki Hospital|Tokushima University
Muraoka, Yuki Kyoto University
Osaka, Rie Kagawa University
Iida‑Miwa, Yuko Kyoto University
Mitamura, Yoshinori Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Tabuchi, Hitoshi Saneikai Tsukazaki Hospital
Kadomoto, Shin Kyoto University
Murakami, Tomoaki Kyoto University
Ooto, Sotaro Kyoto University
Suzuma, Kiyoshi Kagawa University
Tsujikawa, Akitaka Kyoto University
Here, we examined prognostic factors for extremely poor visual outcomes in patients with central retinal vein occlusion (CRVO) in actual practices. We included 150 consecutive eyes with treatment-naïve acute CRVO from four different facilities and observed them for over 24 months. Macular edema (ME) was treated with one or three monthly anti-vascular endothelial growth factor injections (1 or 3 + pro re nata). According to the final Snellen visual acuity (VA), we divided the patients into very poor VA (< 20/200) and control (≥ 20/200) groups and examined risk factors for poor final visual outcomes. The baseline Snellen VA was hand motion to 20/13. The mean number of anti-VEGF injections for ME was 5.3 ± 3.7 during the follow-up period. In total, 49 (32.7%) patients exhibited a very poor final VA; this group comprised significantly older patients with a significantly poorer baseline VA (P < 0.01 for both) than the control group. Comorbid internal carotid artery disease and diabetic retinopathy were significantly associated with a poor final VA. In actual clinical practice, visual outcomes may be extremely poor despite ME treatment in certain patients with CRVO, with advanced age, poor baseline VA, and comorbid internal carotid artery disease and diabetic retinopathy being significant risk factors.
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
|DOI (Published Version)|
|URL ( Publisher's Version )|
srep_10_19667.pdf 1.2 MB